您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Emiglitate(BAY o 1248)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Emiglitate(BAY o 1248)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Emiglitate(BAY o 1248)图片
CAS NO:80879-63-6
规格:98%
分子量:355.38
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议
20mg电议

产品介绍
Emiglitate(BAYo1248)是有效的,竞争选择性的α-glucosidehydrolase抑制剂。
CAS:80879-63-6
分子式:C17H25NO7
分子量:355.38
纯度:98%
存储:Store at -20°C

Background:

Emiglitate (BAY o 1248) is a potent, selective and competitive inhibitor of α-glucoside hydrolase.


Emiglitate greatly suppresses the glucose-stimulated insulin release in parallel with an inhibitory effect on the activities of acid glucan-1,4-α-glucosidase and acid α-glucosidase. In contrast, the activities of acid phosphatase and N-acetyl-β-D-glucosaminidase tend to increase in the presence of the α-glucoside hydrolase inhibitor. The CO-induced amplification of the glucose-stimulated insulin release as well as of the increased activities of the acid α-glucoside hydrolases are abrogated by emiglitate and displayed the same levels as in the absence of CO. The CO-induced rise in the activities of acid phosphatase and acid N-acetyl-β-D-glucosaminidase is not appreciably affected by emiglitate[1].


In fasted rats, emiglitate inducec a significant, dose-dependent increase of hepatic glycogen concentrations. The increase in hepatic glycogen is due to lysosomal storage of glycogen only. Emiglitate in the amount of 5 mg/kg b.wt. does not induce significant changes either of glycogen concentrations or at the EM-level[2].


[1]. Mosén H, et al. Nitric oxide inhibits, and carbon monoxide activates, islet acid alpha-glucoside hydrolase activitiesin parallel with glucose-stimulated insulin secretion. J Endocrinol. 2006 Sep;190(3):681-93. [2]. Lembcke B, et al. Lysosomal storage of glycogen as a sequel of alpha-glucosidase inhibition by the absorbed deoxynojirimycin derivative emiglitate (BAYo1248). A drug-induced pattern of hepatic glycogen storage mimicking Pompe’s disease (glycogenosis type II). Res Exp Med (Berl). 1991;191(6):389-404.